INTEREST in syncope of circulatory origin was stimulated by publication in 1935 of Weiss's 1 monograph describing various clinical syndromes. Subsequently, the mechanisms of some types of syncope have ...

IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 March 10, 2026 2:00 PM EDTCompany ParticipantsMichael Feldschuh ...

If you’ve ever felt dizzy, lightheaded, or like you were about to faint, but you didn’t lose consciousness, you may have experienced presyncope. It can be caused by many conditions, including heart ...

Momentum Over Milestones: Success is not the destination you applaud at the finish line; it is the courage to stay aboard while the landscape blurs, the turns tighten, and the goalpost keeps moving ...

I have had both the responsibility and the privilege of giving many people and their loved ones the diagnosis of psychosis. Technically, psychosis is not a stand-alone diagnosis; it's actually a ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...

Introduction Hypertension programmes have expanded substantially in low-income and middle-income countries, yet treatment and control rates remain insufficient. Programme scale-up may lead to ...

Twenty years after the introduction of the theory, we revisit what it does—and doesn’t—explain. by Clayton M. Christensen, Michael E. Raynor and Rory McDonald Please enjoy this HBR Classic. Clayton M.

Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo ...